Viridian Therapeutics, Inc./DE Long-Term Debt, Maturity, Remainder of Fiscal Year
Viridian Therapeutics, Inc./DE (VRDN) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $1.00 million as of 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2019-11-08
- 2019-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.00M.
- 2019-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.00M.
- 2019-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.33M.
- 2017-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $500.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $2.00M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $2.33M 10-Q · filed 2019-05-09 |
| 2017-09-30 | $500.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $1.00M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $1.50M 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |